Actively Recruiting
Establishing a Clinical Database and Biobank for Schizophrenia：A Cohort Study
Led by Central South University · Updated on 2024-11-25
2000
Participants Needed
4
Research Sites
260 weeks
Total Duration
On this page
Sponsors
C
Central South University
Lead Sponsor
T
The First Affiliated Hospital of Zhengzhou University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a multicenter study conducted in collaboration with Central South University, The First Affiliated Hospital of Zhengzhou University, Nanjing Brain Hospital of Nanjing Medical University, and Anhui Mental Health Center. The project intends to employ standardized diagnostic criteria and clinical assessment procedures to establish a comprehensive cohort of patients with schizophrenia, encompassing all age groups and disease stages, with follow-up periods exceeding one year. The goal is to create an internationally high-standard clinical cohort database and biobank for schizophrenia. Through a multidimensional assessment framework, the project aims to further investigate the etiology of schizophrenia, patterns of disease progression, and clinical outcomes. By periodically capturing dynamic information on risk and preventive factors, the project aims to achieve early diagnosis, early treatment, and improved prognosis for patients. Additionally, it seeks to explore potential biomarkers within the realm of precision medicine that can predict treatment efficacy, providing viable tools for precision healthcare and clinical decision-making in the field of schizophrenia.
CONDITIONS
Official Title
Establishing a Clinical Database and Biobank for Schizophrenia：A Cohort Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of schizophrenia according to ICD-11
- Confirmation of schizophrenia diagnosis using the SCID-5-RV (DSM-5 Structured Clinical Interview for DSM-5 Disorders - Research Version)
You will not qualify if you...
- Diagnosis or assessment confirming neurodevelopmental disorders, bipolar and related disorders, or substance use disorders (excluding alcohol and tobacco)
- Presence of severe or acute physical illnesses such as traumatic brain injury, intracranial space-occupying or infectious diseases, acute cardiovascular or respiratory diseases, and acute hematological disorders
- Presence of clearly defined genetic diseases including tuberous sclerosis, multiple sclerosis, Kleefstra syndrome, 22q11.2 deletion syndrome, Prader-Willi syndrome, and Klinefelter syndrome (47,XXY)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Anhui Mental Health Center
Hefei, Anhui, China
Active, Not Recruiting
2
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450052
Active, Not Recruiting
3
Mental Health Institute of Second Xiangya Hospital,CSU
Changsha, Hunan, China, 410011
Actively Recruiting
4
Nanjing Brain Hospital, Nanjing Medical University
Nanjing, Jiangsu, China, 210029
Active, Not Recruiting
Research Team
R
Renrong Wu, M.D., Ph.D.
CONTACT
H
Hui Tang, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here